Results 21 to 30 of about 126,758 (293)

Rejection of Experimental Hodgkins Lymphoma by T-cells Engineered with a CD19 Chimeric Antigen Receptor [PDF]

open access: yes, 2012
T cells engineered to express chimeric receptors combining an external antibody binding domain with the CD3ζ T cell receptor (TCR) internal domain for triggering cell activation are being used for immunotherapeutic targeting of tumour cells in a non-HLA ...
Cheadle, Eleanor   +8 more
core   +1 more source

Purification and Immunophenotypic Characterization of Human CD19+CD24hiCD38hi and CD19+CD24hiCD27+ B Cells [PDF]

open access: yes, 2021
Regulatory B cells (Bregs) have immunosuppressive capacity, primarily via the production of IL-10. IL-10 expression and immunosuppression have been described in a number of human B cell subsets, two of which include the CD19+CD24hiCD38hi and CD19+CD24hiCD27+ populations.
Bradford, HF, Mauri, C
openaire   +3 more sources

Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients

open access: yesTurkish Journal of Hematology, 2020
Objective: Relapsed and refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are the focus of studies on hematological cancers.
Cihan Taştan   +21 more
doaj   +1 more source

Efficient Transduction of T-Lymphocytes by Lentiviral Particles in Oncoimmunological Studies

open access: yesКлиническая онкогематология, 2020
Aim. To compare different methods of lentivirus concentration in order to select the best way of providing high-level transduction for generating laboratory CAR-T cells. Materials & Methods. Concentration of lentiviral supernatant was carried out by 4
Ekaterina Konstantinovna Zaikova   +5 more
doaj   +1 more source

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement

open access: yeshealthbook TIMES. Oncology Hematology, 2019
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting.
Antonia Maria S. Müller, Alexander Ring
doaj   +1 more source

Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy?

open access: yesBlood Cancer Journal, 2023
CD19 chimeric antigen receptor (CAR) T-cell therapy has shown great success against B-cell acute lymphoblastic leukemia (B-ALL). Tandem and sequential CD19/CD22 dual-target CAR T-cell therapies have been developed to reduce the possibility of CD19 ...
Sining Liu   +21 more
doaj   +1 more source

A Lower Proportion of Regulatory B Cells in Patients with Henoch-Schoenlein Purpura Nephritis. [PDF]

open access: yesPLoS ONE, 2016
BACKGROUND:Henoch-Schoenlein purpura is the one of most common types of systemic vasculitis that involves impaired renal function and Henoch-Schoenlein purpura nephritis (HSPN).
Xintong Hu   +7 more
doaj   +1 more source

Self-Immolative Carbamate Linkers for CD19-Budesonide Antibody-Drug Conjugates

open access: yes, 2023
Antibody-drug conjugates consist of potent small molecule payloads linked to a targeting antibody. Payloads must possess a viable functional group by which a linker for conjugation can be attached.
Axel, Hernandez, Jr.   +12 more
core   +1 more source

Generation and characterization of CD19-iCre mice as a tool for efficient and specific conditional gene targeting in B cells

open access: yesScientific Reports, 2021
The Cre/loxP system is a powerful tool for generating conditional gene knockout (KO) mice and elucidate gene function in vivo. CD19-Cre and Mb1-iCre transgenic mice are commonly used for generating B cell-specific KO mice and investigate the development,
Tomoharu Yasuda   +5 more
doaj   +1 more source

Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia

open access: yesOncoImmunology, 2018
CD19 immunotherapies based on T cells opened new avenues in the treatment of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, Fc engineered CD19 antibodies may also bear great potential.
Christian Kellner   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy